Meclofenamic Acid
Recurrent Brain Metastases
Memorial Sloan Kettering Cancer CenterN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent Brain Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Massachusetts General Hospital | Phase 2 | CCC |
CABAZITAXEL AIO-Studien-gGmbH | Phase 2 | CCC |
Palbociclib Massachusetts General Hospital | Phase 2 | CCC |
Pembrolizumab Massachusetts General Hospital | Phase 2 | CCC |
Cyclophosphamide Massachusetts General Hospital | Phase 2 | CCC |
Same molecule, other indications
Meclofenamic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →